Naveen Pemmaraju, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX, gives an overview of clinical trials of treatments for myeloproliferative neoplasms (MPNs) ongoing in 2021. Dr Pemmaraju talks on the emerging combinatorial approach which may be increasingly observed in upcoming studies as well as the increased inclusion of patient reported outcomes to better assess symptom burden. Dr Pemmaraju further talks on how online tools can be utilized to improve the presence of ongoing clinical trials and communication with patients. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.